Drug intelligence / Profile preview

Conditioned Medium + Umbilical Cord Mesenchymal Stem Cells

Development stage: Unknown
Lead developer: Prodia Stem Cell Indonesia
Modality: Cell Therapies
Administration: Intranasal, Intraparenchymal

Overview

This investigational combination therapy is being developed by PT. Prodia Stem Cell Indonesia (ProSTEM) for the treatment of acute ischemic stroke. The therapy consists of two distinct biological components: a conditioned medium (CM) and umbilical cord-derived mesenchymal stem cells (UC-MSCs). The conditioned medium is the growth medium harvested from stem cell cultures, containing a secretome of growth factors, cytokines, and other signaling molecules with therapeutic potential. The UC-MSCs are live stem cells derived from umbilical cord tissue. The treatment protocol utilizes a dual-delivery approach: the conditioned medium is administered intranasally to leverage the nose-to-brain pathway for rapid delivery of neurotrophic factors, while the UC-MSCs are delivered via direct intraparenchymal injection into the brain. This combination aims to induce neurogenesis, provide neurotrophic support to damaged neural tissue, and modulate neuroinflammation to promote functional recovery following a stroke.

Other names: CM + UC-MSCsConditioned Medium and Umbilical-derived Mesenchymal Stem Cellconditioned medium-PT. Prodia Stem Cell Indonesia-ischemic stroke

Beyond the preview

Go deeper on Conditioned Medium + Umbilical Cord Mesenchymal Stem Cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Conditioned Medium + Umbilical Cord Mesenchymal Stem Cells.

Explore the full profile